1. Trial of d-alpha-tocopherol in Huntington's disease.
- Author
-
Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR, Bylsma F, Coyle JT, McHugh PR, and Folstein SE
- Subjects
- Chromosomes, Human, Pair 4 genetics, Double-Blind Method, Humans, Huntington Disease genetics, Isomerism, Oxidative Stress drug effects, Placebos, Prospective Studies, Treatment Outcome, Vitamin E pharmacology, Antioxidants therapeutic use, Huntington Disease drug therapy, Vitamin E therapeutic use
- Abstract
Objective: Evidence suggests that the neuropathology of Huntington's disease, a neuropsychiatric disorder due to a mutation on chromosome 4, results from excessive activation of glutamate-gated ion channels, which kills neurons by oxidative stress. Therefore, the authors hypothesized that alpha-tocopherol, which reduces oxyradical damage to cell membranes, might slow the course of Huntington's disease., Method: A prospective, double-blind; placebo-controlled study of high-dose d-alpha-tocopherol treatment was carried out with a cohort of 73 patients with Huntington's disease who were randomly assigned to either d-alpha-tocopherol or placebo. Patients were monitored for changes in neurologic and neuropsychologic symptoms., Results: Treatment with d-alpha-tocopherol had no effect on neurologic and neuropsychiatric symptoms in the treatment group overall. However, post hoc analysis revealed a significant selective therapeutic effect on neurologic symptoms for patients early in the course of the disorder., Conclusions: Antioxidant therapy may slow the rate of motor decline early in the course of Huntington's disease.
- Published
- 1995
- Full Text
- View/download PDF